Sign in to view content

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO

Nikhil K Bommakanti, MD

Video
Published 2024

Related

Durability of Combination Therapy of Sozinibercept, an Anti-VEGF-C/D 'Trap' With Ranibizumab in nAMD or Aflibercept in DME
Nathan C. Steinle, MD
Annual Meeting Talks
2024
How Do I Decide to Treat Patients with Geographic Atrophy?
Glenn J. Jaffe, MD
Updates from the Field
2024
Modifier-25 Examinations Reduce Travel Burden, Decrease Treatment Cost, and Improve QALY for Exudative Age-Related Macular Degeneration Patients
Henry A Leder, MD
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more